(This Feb 6. story has been corrected to show the damages are according to an expert report, and not estimated by IHH's unit.

The Japanese pharma had one asset rejected by the FDA and withdrew a regulatory application for another, but already this ...

Several medicines are poised to reach new heights after winning key endorsements from European drug regulators. | Among those ...

Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief ...

Daiichi Sankyo is turning to the German city of Heidelberg for help developing antibodies. The Japanese pharma giant is teaming up with independent research institute BioMed X to form a new ...

This is just the latest step Daiichi Sankyo has taken to achieve its five-year goals. In January of this year, the company announced a new smart research facility in San Diego. 2 The goal of this ...

TOKYO, January 31, 2025--(BUSINESS WIRE)--Daiichi Sankyo Company, Ltd (TSE: 4568) has appointed Hiroyuki Okuzawa, 62, to succeed Sunao Manabe, DVM, Ph.D. as Chief Executive Officer (CEO ...